**Core Concept**
Liver cancer, particularly hepatocellular carcinoma (HCC), is a significant cause of morbidity and mortality worldwide. Early detection and screening of high-risk populations are crucial for improving outcomes. The USPSTF recommends screening for HCC in individuals with chronic liver disease.

**Why the Correct Answer is Right**
Alpha-fetoprotein (AFP) is a tumor marker that is commonly used for screening HCC in high-risk populations. Elevated levels of AFP are associated with liver cancer, although it is not specific for HCC. However, in the context of chronic liver disease, an elevated AFP level can be a useful indicator of HCC. The American Association for the Study of Liver Diseases (AASLD) recommends screening for HCC in individuals with chronic liver disease using a combination of ultrasound and AFP levels.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because while liver function tests (LFTs) can indicate liver damage, they are not specific for HCC and are not recommended as a screening tool.
**Option B:** This option is incorrect because while imaging modalities like CT and MRI are useful for diagnosing HCC, they are not typically used for screening high-risk populations.
**Option C:** This option is incorrect because while liver biopsy is a diagnostic tool for liver disease, it is not a practical or safe option for screening high-risk populations.

**Clinical Pearl / High-Yield Fact**
The AASLD recommends screening for HCC in individuals with chronic liver disease using a combination of ultrasound and AFP levels every 6-12 months.

**Correct Answer:** C.